Literature DB >> 7548504

Nosocomial candidemia: risk factors and attributable mortality.

R P Wenzel1.   

Abstract

Over the past decade, the incidence of hospital-acquired bloodstream infections caused by Candida species has risen and the species associated with such infections have changed. The incidence of candidemia is dramatically higher in high-risk, critical-care units than in other parts of the hospital. Certain underlying physical conditions including acute leukemia, leukopenia, burns, gastrointestinal disease, and premature birth predispose patients to nosocomial candidemia. Independent risk factors include prior treatment with multiple antibiotics, prior Hickman catheterization, isolation of Candida species from sites other than the blood, and prior hemodialysis. In this article some of the challenges posed by the management of nosocomial candidemia are presented in three case studies. In addition, the results of several investigations of nosocomial candidemia at the University of Iowa Hospitals and Clinics are reviewed.

Entities:  

Mesh:

Year:  1995        PMID: 7548504     DOI: 10.1093/clinids/20.6.1531

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  110 in total

1.  Deletion of the two-component histidine kinase gene (CHK1) of Candida albicans contributes to enhanced growth inhibition and killing by human neutrophils in vitro.

Authors:  Antonella Torosantucci; Paola Chiani; Flavia De Bernardis; Antonio Cassone; Jose Antonio Calera; Richard Calderone
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  Estimating attributable mortality of candidemia: clinical judgement vs matched cohort studies.

Authors:  S I Blot; K H Vandewoude
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-18       Impact factor: 3.267

3.  Emerging Issues in Nosocomial Fungal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

4.  C. albicans increases cell wall mannoprotein, but not mannan, in response to blood, serum and cultivation at physiological temperature.

Authors:  Michael Kruppa; Rachel R Greene; Ilka Noss; Douglas W Lowman; David L Williams
Journal:  Glycobiology       Date:  2011-04-21       Impact factor: 4.313

Review 5.  Prophylaxis and treatment of invasive candidiasis in the intensive care setting.

Authors:  L Ostrosky-Zeichner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

6.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

7.  Long-term follow-up of patients with candiduria.

Authors:  S G Revankar; M S Hasan; V S Revankar; J D Sobel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-22       Impact factor: 3.267

Review 8.  Candida albicans Biofilms and Human Disease.

Authors:  Clarissa J Nobile; Alexander D Johnson
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

Review 9.  Candida infections of medical devices.

Authors:  Erna M Kojic; Rabih O Darouiche
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 10.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.